Veeva’s Antitrust Lawsuit Against IQVIA Advances

Veeva expands legal action to cover additional Veeva software applications as IQVIA attempts to extend monopoly control

Favorable ruling would finally give life sciences companies the freedom to use the software and data products of their choice.

Veeva Systems announced it is gaining widespread customer support for its antitrust lawsuit against. Six of the largest global pharmaceutical companies were among more than 70 depositions gathered as part of the fact discovery phase of the case.

As its initial lawsuit advances, Veeva filed a motion this week to expand its legal action to include additional Veeva software applications that IQVIA is excluding customers from using with IQVIA data.

“Competition and an open market are key to a healthy economy and are essential in technology, software, and data markets,” said Doug Bernheim, chair of the department of economics at Stanford University and partner at Bates White, LLC. “Antitrust law defends customers from any one company asserting their power and control over customers’ choices, and the law should be enforced when the economy is deprived of the benefits of competition.”

Full Content: Pharma Live

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.